Physician profile
Michael A Graceffo
NPI 1295799492
$7,889.05
in general payments reported to CMS, 2019-2025
37 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $238 · 2021: $916 · 2022: $1,640 · 2023: $1,816 · 2024: $1,561 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,549 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,549.01 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $817.17 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $805.62 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $641.03 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $573.83 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $539.24 | 2022-2024 | Verquvo |
| Amgen INC. | $502.84 | 2019-2023 | Repatha |
| Pfizer INC. | $501.40 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $446.83 | 2019-2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $352.46 | 2019-2025 | Bodyguardian, Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $335.28 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $290.08 | 2021-2022 | |
| Abbott Laboratories | $255.53 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $229.40 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $197.04 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $142.17 | 2019-2024 | Opsumit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $137.86 | 2022-2024 | Barostim Neo System |
| Biosense Webster, INC. | $129.20 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $111.19 | 2019-2024 | Onpattro |
| Amarin Pharma, INC. | $96.02 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $84.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $79.45 | 2019-2021 | |
| Vital Connect, INC | $78.11 | 2023 | Vitalpatch Rtm |
| Bardy Diagnostics, INC. | $75.00 | 2019-2020 | |
| Edwards Lifesciences Corporation | $63.93 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $61.55 | 2023-2024 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $46.44 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $43.87 | 2019-2021 | |
| Althera Pharmaceuticals LLC | $42.44 | 2021-2022 | |
| Scpharmaceuticals INC. | $38.39 | 2023-2024 | |
| Lundbeck LLC | $35.02 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.78 | 2023 | Arcalyst |
| Philips North America LLC | $26.34 | 2023 | |
| Tactile Systems Technology INC | $23.71 | 2023 | Flexitouch Plus, Entre Plus |
| Braemar Manufacturing, LLC | $15.72 | 2019 | |
| Atricure, INC. | $14.32 | 2022 | |
| Convatec INC. | $14.14 | 2022 | |
| Cashflow Solutions, LLC | $13.41 | 2023 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Graceffo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.